Fig. 1.
Signalling pathways activated by drugs potentially affecting BAT activity and function: AMP-activated protein kinase (AMPK), adrenoceptor beta 3 (β3-AR), branched-chain amino acids (BCAA), branched-chain keto acids (BCKA), farnesoid X receptor (FXR), gastric inhibitory polypeptide receptor (GIPR), glucagon-like peptide 1 receptor (GLP-1R), Glucagon G-coupled receptor (GCGR), sirtuin-1 (SIRT1), peripheral nervous system (PNS), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), phosphatidylinositol-3 kinase (PI3K), PR domain-containing protein 16 (PRDM16), protein kinase A (PKA), protein kinase B (AKT), p38α mitogen-activated protein kinase (p38 MAPK), ginsenoside Rb1 (Rb1), sympathetic nervous system (SNP), exchange protein directly activated by cAMP (EPAC), EPAC specific inhibitor (ESI-09), CCAAT enhancer-binding protein α (CEBPα), tricarboxylic acid (TCA) cycle, tumour necrosis factor receptor (TNFR), tumour necrosis factor α (TNF-α), thyroid receptor (TR)
